Liabilities / Assets
64th percentile
Higher debt load relative to assets than 64% of similar nonprofits.
Watching Over Mothers & Babies Foundation
EIN 52-2420995 • 501(c)3 • Tucson, AZ
RevokedPub. 78 Eligible
Profile
The Watching Over Mothers & Babies Foundation (WOMB) is partnering with local and national organizations to address a broad array of health problems that continue to impact women and their children.
Siviq Scores
Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.
0.00x
Liabilities / Revenue
70th percentile
Higher debt load relative to revenue than 70% of similar nonprofits.
Net Margin
8th percentile
Higher net margin than 8% of similar nonprofits.
Top Officer Pay
81st percentile
Higher top officer pay than 81% of similar nonprofits.
Top officer pay equals 0.0% of source-year revenue.
Asset Growth
25th percentile
Faster asset growth than 25% of similar nonprofits.
Revenue Growth
19th percentile
Faster revenue growth than 19% of similar nonprofits.
Balance Sheet
Assets
Down$177,956
Down $87,623 (-33%) from 2023
Liabilities
Down$729
Down $1,136 (-61%) from 2023
Net Assets
Down$177,227
Down $86,487 (-33%) from 2023
Revenue
Down$68,014
Down $60,495 (-47%) from 2023
Expenses
Down$157,058
Down $30,196 (-16%) from 2023
Net Income
Down-$89,044
Down $30,299 (-52%) from 2023
Trend Graphs
Filings
Most recent year
2024 • Form 990EZDetailed filing. Detailed filing data is available for this year.
- Assets
- $177,956
- Liabilities
- $729
- Net assets
- $177,227
- Revenue
- $68,014
- Expenses
- $157,058
- Net income
- -$89,044
Latest Filing Detail
Jump To
Filing Snapshot
- Filing Period
- Jul 1, 2023 to Jun 30, 2024
- Signed
- May 14, 2025
- Return Version
- 2023v6.0
- Gross Receipts
- $68,014
Mission and Program Overview
Mission
The Watching Over Mothers & Babies Foundation (WOMB) is partnering with local and national organizations to address a broad array of health problems that continue to impact women and their children.
The watching over mothers & babies foundation (womb) helps mothers with perinatal health problems and is partnering with local and national organizations to address a broad array of perinatal health problems.
Program Services
| Description | Grants | Expenses |
|---|---|---|
| THE WATCHING OVER MOTHERS & BABIES (WOMB) FOUNDATIONCONDUCTS PRIMARY CLINICAL RESEARCH AND COLLABORATES WITH INDUSTRY TO IMPROVE MATERNAL-CHILD HEALTH. THIS WORK HAS LED TO THE DEVELOPMENT AND IMPLIMENTATION OF NEW TECHNOLOGIES WHICH OFFER PREGNANT WOMEN AND THEIR CHILDREN NEW DIAGNOSTIC AND THERAPUETIC OPTIONS IN THE GOAL OF IMPROVING PERINATAL & NEONATAL OUTCOMES. HISTORICALLY WOMB WAS ENGAGED IN A COMBINATION OF INNOVATIVE RESEARCH DEVOTED TO THE TREATMENT OF TOBACCO USE IN PREGNANCY IN AN EFFORT TO INCREASE CESSATION RATES AMONG PREGNANT WOMEN. WHILE THAT GOAL REMAINS, WOMB HAS DIVERSIFIED AND IS COMMITTED TO ADDRESSING OTHER IMPORTANT HEALTH INITIATIVES MOST RECENTLY WOMB HAS APPLIED FOR RESEARCH FUNDING TO APPLY SEVERAL OF THE SAME PRINCIPLES TO OPIOID DEPENDENCE DISORDER IN AN EFFORT TO BETTER MANAGE OPIOID USE IN PREGNANCY. WOMB IS STILL EVALUATING ITS SUCCESS WITH MOTIVATIONAL COUNSELING DIRECTED AT THE PREGNANT WOMEN AND WOMAN'S PARTNER TO ASSIST IN THE SMOKING CESSATION. THIS PROJECT IS CALLED "FAMILY ALLIANCE AND COMPARES MOTIVATIONAL COUNSELING TO THE STANDARD PRESCRIPTIVE TECHNIQUES, COMMONLY USED IN CLINICAL PRACTICE. THE ARIZONA BIOMEDICAL RESEARCH COMMISSION PROVIDED THE EARLY FUNDING FOR THIS TRIAL. IN THE EARLY PHASE OF THIS STUDY, DR. MILLER WAS STILL FULL-TIME FACULTY AT THE UNIVERSITY OF ARIZONA, HOWEVER UPON LEAVING HIS POSITION, HE DESIRED TO CONTINUE THIS WORK THROUGH THE CREATION OF THE WOMB FOUNDATION.IN THE PAST SEVERAL YEARS WOMB HAS BECOME MORE INVOLVED IN VACCINE RESEARCH. THE WORK WAS FOCUSED ON REDUCING THE RISK OF COVID AND RSV BY IMMUNIZING PREGNANT WOMEN AND CONVEYING PASSIVE IMMUNITY TO THE FETUS AS WE DO WITH SEVERAL OTHER VIRAL INFECTIONS SUCH AS INFLUENZA AND PERTUSSIS. THIS WORK BECAME EVEN MORE IMPORTANT OVER THE PAST FEW YEARS AS OPPORTUNITIES TO STUDY COVID EMERGED. THE GOAL OF SIGNIFICANTLY REDUCING RSV IN THE NEONATE ALONG WITH THE MORBIDITY AND MORTALITY CONTINUES TO BE A SERIOUS PROBLEM. AS A RESULT, MORE COMPANIES HAVE ENTERED THE FIELD AND THE COMMITMENT TO THIS RESEARCH QUESTION HAS EXPANDED. WOMB HAS BEEN FORTUNATE TO PLAY A SMALL ROLL IN THIS RESEARCH. THIS WORK BRIDGES THE MATERNAL-NEONATAL FIELDS WHICH HISTORICALLY HAS BEEN DIFFICULT TO DO. LOOKING FORWARD THERE WILL BE ONGOING OPPORTUNITIES TO EXPAND ON THIS WORK AS ADDITIONAL RSV VACCINES ARE STUDIED. THERE IS ALSO THE POTENTIAL OPPORTUNITY TO STUDY GBS VACCINATION WHICH IF CONFIRMED TO PROVIDE ADEQUATE PROTECTION WOULD DRAMATICALLY CHANGE HOW WE CURRENTLY MANAGE THIS PERINATAL RISK. OTHER ACTIVE RESEARCH ACTIVITIES INCLUDE:1.PFIZER DEVELOPED AN RSV VACCINE AND BROUGHT IT TO THE CLINICAL MARKET IN AUGUST 2023. THE RCT THAT ENABLED THIS NOVEL PRODUCT WAS LAUNCHED IN 2018. A PHASE 2B RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PERFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY. THE ENROLLMENT FOR THIS STUDY SPANNED SEVERAL YEARS BECAUSE OF THE SEASONALITY OF RSV. PFIZER RECEIVED FDA APPROVAL FOR THIS NOVEL THERAPY BUT AS PART OF THAT APPROVAL WAS REQUIRED TO CONTINUE MATERNAL AND NEONATAL SURVIELLANCE FOR A PERIOD OF 24 MONTHS WHICH IS ONGING. WE CONTINUE TO PARTICIPATE IN THIS TRIAL SINCE THE MATERNAL AND FETAL OUTCOME EXTEND 24 MONTHS PAST DELIVERY.2. GSK ALSO INITIATED ITS OWN RSV VACCINE TRIAL IN 2021. THE PROPRIETRY FORMULATION IS DIFFERENT, BUT THE BASIC CONSTRUCT OF THE PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL IS SIMILAR. THIS INTERNATIONAL TRIAL WAS DESIGNED TO ESTABLISH THE EFFICACY OF A SINGLE DOSE OF UNADJUVANTED RSV MATERNAL VACCINE, ADMINISTERED IM TO PREGNANT WOMEN 18 TO 49 YEARS OF AGE, FOR PREVENTION OF RSV ASSOCIATED LRTI IN THEIR INFANTS UP TO 6 MONTHS OF AGE. THE DSMB NOTICED A DISTURBING SAFETY SIGNAL AND CALLED FOR THE TRIAL TO BE HAULTED. SUBSEQUENTLY GSK SUSPENDED THE TRIAL BUT HAS COMMITTED TO LONGER TERMS SURVIELLANCE OF THE STUDY SUBJECTS.3. WHILE WOMB REMAINS COMMITTED TO BREAST FEEDING, WE RECOGNIZE THAT THERE ARE MANY WOMEN WHO ARE EITHER INCAPABLE OR UNABLE TO BREAST FEED THEIR CHILDREN. THESE WOMEN NEED THE BEST ALTERNATIVE TO BREAST MILK. FOR SOME DONOR BREAST MILK IS THE BEST OPTION, BUT IMPROVED FORMULAS REMAIN AN IMPORTANT NUTRITIONAL OPTION. WOMB IS CURRENTLY PARTICIPATING IN MULTI CENTER MEDICAL DATA COLLECTION IN SUBJECTS PREVIOUSLY ENROLLED IN BY HEART PROTOCOL SS-101-18 BY HEART NEW INFANT FORMULA BH101184. COOK STUDY: RCT COMPARING THE CRB WITH PITOCIN TO PITOCIN ALONE INPREMATURE RUPTURE OF MEMBRANES (PROM) PATIENTS WITH AN UNFAVORABLE CERVIX WAS COMPLETED THIS YEAR AND DATA ANALYSIS IS ONGOING. WE PRESENTED THE RESULTS AT THE ANNUAL SMFM MEETING AND ARE REVIEWING NEXT STEPS.5. ACTIM PARTUS TEST: IS A STUDY DESIGNED TO EVALUATE A NEW DIAGNOSTIC TECHNOLOGY TO DETECT PRETERM LABOR AT AN EARLY STAGE WHERE IT MIGHT BETREATED AVOIDING THE SERIOUS CONSEQUENCES OF A PRETERM BIRTH (PTB).THIS STUDY WAS ALSO COMPLETED AND IS UNDER REVIEW BY THE FDA.6. WOMB WAS COLLABORATING WITH COMMON SENSE IN THE DEVELOPEMENT OF AN INNOVATIVE APPROACH TO DIAGNOSE PRETERM RUPTURE OF MEMBRANES THAT WOULD HAVE OFFERRED WOMEN A METHOD OF ASSESSING PPROM MANIFEST BY LEAKING PRIOR TO PRESENTING TO THE HOSPITAL. MANY WOMEN DELAY OR DON'T SEEK VITAL EVALUATION BECAUSE THEY INTERPRET LEAKING AS INCONTINENCE. UNFORTUNATELY, THIS CAN LEAD TO ADVERSE PERINATAL OUTCOME. CONVERSELY FREQUENT HOSPITAL EVLAUATIONS CAN BE COSTLY AND CONSUMES CONSIDERABLE CLINICAL RESOURCES. THE PURPOSE OF THIS STUDY WAS TO COMPARE THIS NEW TECHNOLOGY WITH THE CURRENT STANDARD OF CARE. THIS STUDY WAS CONCLUDED AND THE RESULTS ARE UNDER REVIEW BY THE FDA. DURING THIS PERIOD COMMON SENSE EXPERIENCED FINANCIAL CHALLENGES THAT LED THE COMPANY TO GO OUT OF BUSINESS. CONSEQUENLY THIS WORK WILL NOT CONTINUE IN ITS CURRENT FORM.7. WOMB HAS BEEN INVOLVED IN PRENATAL DIAGNOSTIC TESTING AND CONTINUES TO EXPLORE RELATIONSHIPS THAT COULD LEAD TO THE OPPORTUNITY TO TEST NEW DIAGNOSTIC PLATFORMS. THERE ARE NO CURRENT AGREEMENTS BUT THIS AREA OF PERINATAL MEDICINE CONTINUES TO EXPAND AND INCREASINGLY OFFERS NEW OPTIONS. | $0 | $157,058 |
Compensation and Service Providers
Employees
| Name | Title | Full / Part Time | Base | Other | Total |
|---|---|---|---|---|---|
| DR HUGH MILLER | President/CEO | PT | $0 | - | - |
| MICHELLE BROWN | COO/Counsel | PT | $0 | - | - |
| DR MONICA CASPER | Secretary/Treasurer | - | $0 | - | - |
| KENNETH RAMOS | Member | - | $0 | - | - |
| RALPH FREGOSI | Member | - | $0 | - | - |
| PENNY BUSSEL-STANSFIELD | Member | - | $0 | - | - |
Filing and Contact Details
Filer
- Filer Name
- Watching Over Mothers & Babies
- EIN
- 52-2420995
- Phone
- 5209071461
- Address
- CO HUGH MILLER, TUCSON, AZ 85712
Signing Officer
- Name
- Dr Hugh Miller
- Title
- CEO
- Phone
- 5209071461
- Signed
- 2025-05-14
- Discuss with paid preparer
- Yes
Preparer
- Firm
- Hbl Cpas Pc
- Address
- 5470 E BROADWAY BLVD, TUCSON, AZ 85711
- Preparer
- Laura Randol
- Phone
- 5208863181
Supplemental Narrative
Additional Explanations
Form 990-ez, Part I, Line 4 - Other Investment Income
“Description: interest income. Amount: 17.”
Form 990-ez, Part I, Line 16 - Other Expenses
“Description: insurance. Amount: 9,758. Description: telephone . Amount: 2,121. Description: bank charges. Amount: 111. Description: interest expense. Amount: 58. Description: office supplies. Amount: 3,562. Description: calibration. Amount: 1,340. Description: penalties. Amount: 896. Total to form 990-ez, line 16: 17,846.”
Form 990-ez, Part I, Line 20 - Other Changes in Net Assets
“Description: prior period adjustments. Amount: 2,557.”
Form 990-ez, Part II, Line 26 - Other Liabilities
“Description: accounts payable. Beg. Of year amount: 1,865. End of year amount: 729.”
Raw XML Appendix147 raw XML fields
This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.
| Path | # | Value |
|---|---|---|
| IRS990EZ/ActivitiesNotPreviouslyRptInd | 0 | 0 |
| IRS990EZ/BooksInCareOfDetail/BusinessName/BusinessNameLine1Txt | 0 | THE ORGANIZATION |
| IRS990EZ/BooksInCareOfDetail/PhoneNum | 0 | 5208829662 |
| IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt | 0 | 5245 E KNIGHT DRIVE |
| IRS990EZ/BooksInCareOfDetail/USAddress/CityNm | 0 | TUCSON |
| IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd | 0 | AZ |
| IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd | 0 | 85712 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt | 0 | 265579 |
| IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt | 0 | 177956 |
| IRS990EZ/ChgMadeToOrgnzngDocNotRptInd | 0 | 0 |
| IRS990EZ/DirectIndirectPltclExpendAmt | 0 | 0 |
| IRS990EZ/DonorAdvisedFndsInd | 0 | 0 |
| IRS990EZ/EngagedInExcessBenefitTransInd | 0 | 0 |
| IRS990EZ/ExcessOrDeficitForYearAmt | 0 | -89044 |
| IRS990EZ/FeesAndOtherPymtToIndCntrctAmt | 0 | 9153 |
| IRS990EZ/FiledScheduleAInd | 0 | 1 |
| IRS990EZ/ForeignFinancialAccountInd | 0 | 0 |
| IRS990EZ/ForeignOfficeInd | 0 | 0 |
| IRS990EZ/Form990TotalAssetsGrp/BOYAmt | 0 | 265579 |
| IRS990EZ/Form990TotalAssetsGrp/EOYAmt | 0 | 177956 |
| IRS990EZ/GrossReceiptsAmt | 0 | 68014 |
| IRS990EZ/InfoInScheduleOPartIIIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartIInd | 0 | X |
| IRS990EZ/InfoInScheduleOPartVInd | 0 | X |
| IRS990EZ/InvestmentIncomeAmt | 0 | 17 |
| IRS990EZ/LobbyingActivitiesInd | 0 | 0 |
| IRS990EZ/MadeLoansToFromOfficersInd | 0 | 0 |
| IRS990EZ/MethodOfAccountingAccrualInd | 0 | X |
| IRS990EZ/NetAssetsOrFundBalancesBOYAmt | 0 | 263714 |
| IRS990EZ/NetAssetsOrFundBalancesEOYAmt | 0 | 177227 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt | 0 | 263714 |
| IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt | 0 | 177227 |
| IRS990EZ/OccupancyRentUtltsAndMaintAmt | 0 | 31230 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 0 | 30.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 1 | 20.00 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 2 | 0.20 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 3 | 0.20 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 4 | 0.20 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt | 5 | 0.20 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 4 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt | 5 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 4 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/EmployeeBenefitProgramAmt | 5 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 0 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 1 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 2 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 3 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 4 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/ExpenseAccountOtherAllwncAmt | 5 | 0 |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 0 | DR HUGH MILLER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 1 | MICHELLE BROWN |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 2 | DR MONICA CASPER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 3 | KENNETH RAMOS |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 4 | RALPH FREGOSI |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm | 5 | PENNY BUSSEL-STANSFIELD |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 0 | PRESIDENT/CEO |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 1 | COO/COUNSEL |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 2 | SECRETARY/TREASURER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 3 | MEMBER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 4 | MEMBER |
| IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt | 5 | MEMBER |
| IRS990EZ/OperateHospitalInd | 0 | 0 |
| IRS990EZ/Organization501c3Ind | 0 | X |
| IRS990EZ/OrganizationDissolvedEtcInd | 0 | 0 |
| IRS990EZ/OrganizationHadUBIInd | 0 | 0 |
| IRS990EZ/OtherChangesInNetAssetsAmt | 0 | 2557 |
| IRS990EZ/OtherExpensesTotalAmt | 0 | 17846 |
| IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt | 0 | NONE |
| IRS990EZ/PartVIOfCompOfHghstPdEmplTxt | 0 | NONE |
| IRS990EZ/PoliticalCampaignActyInd | 0 | 0 |
| IRS990EZ/PrimaryExemptPurposeTxt | 0 | THE WATCHING OVER MOTHERS & BABIES FOUNDATION (WOMB) HELPS MOTHERS WITH PERINATAL HEALTH PROBLEMS AND IS PARTNERING WITH LOCAL AND NATIONAL ORGANIZATIONS TO ADDRESS A BROAD ARRAY OF PERINATAL HEALTH PROBLEMS. |
| IRS990EZ/PrintingPublicationsPostageAmt | 0 | 1330 |
| IRS990EZ/ProgramServiceRevenueAmt | 0 | 67997 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt | 0 | THE WATCHING OVER MOTHERS & BABIES (WOMB) FOUNDATIONCONDUCTS PRIMARY CLINICAL RESEARCH AND COLLABORATES WITH INDUSTRY TO IMPROVE MATERNAL-CHILD HEALTH. THIS WORK HAS LED TO THE DEVELOPMENT AND IMPLIMENTATION OF NEW TECHNOLOGIES WHICH OFFER PREGNANT WOMEN AND THEIR CHILDREN NEW DIAGNOSTIC AND THERAPUETIC OPTIONS IN THE GOAL OF IMPROVING PERINATAL & NEONATAL OUTCOMES. HISTORICALLY WOMB WAS ENGAGED IN A COMBINATION OF INNOVATIVE RESEARCH DEVOTED TO THE TREATMENT OF TOBACCO USE IN PREGNANCY IN AN EFFORT TO INCREASE CESSATION RATES AMONG PREGNANT WOMEN. WHILE THAT GOAL REMAINS, WOMB HAS DIVERSIFIED AND IS COMMITTED TO ADDRESSING OTHER IMPORTANT HEALTH INITIATIVES MOST RECENTLY WOMB HAS APPLIED FOR RESEARCH FUNDING TO APPLY SEVERAL OF THE SAME PRINCIPLES TO OPIOID DEPENDENCE DISORDER IN AN EFFORT TO BETTER MANAGE OPIOID USE IN PREGNANCY. WOMB IS STILL EVALUATING ITS SUCCESS WITH MOTIVATIONAL COUNSELING DIRECTED AT THE PREGNANT WOMEN AND WOMAN'S PARTNER TO ASSIST IN THE SMOKING CESSATION. THIS PROJECT IS CALLED "FAMILY ALLIANCE AND COMPARES MOTIVATIONAL COUNSELING TO THE STANDARD PRESCRIPTIVE TECHNIQUES, COMMONLY USED IN CLINICAL PRACTICE. THE ARIZONA BIOMEDICAL RESEARCH COMMISSION PROVIDED THE EARLY FUNDING FOR THIS TRIAL. IN THE EARLY PHASE OF THIS STUDY, DR. MILLER WAS STILL FULL-TIME FACULTY AT THE UNIVERSITY OF ARIZONA, HOWEVER UPON LEAVING HIS POSITION, HE DESIRED TO CONTINUE THIS WORK THROUGH THE CREATION OF THE WOMB FOUNDATION.IN THE PAST SEVERAL YEARS WOMB HAS BECOME MORE INVOLVED IN VACCINE RESEARCH. THE WORK WAS FOCUSED ON REDUCING THE RISK OF COVID AND RSV BY IMMUNIZING PREGNANT WOMEN AND CONVEYING PASSIVE IMMUNITY TO THE FETUS AS WE DO WITH SEVERAL OTHER VIRAL INFECTIONS SUCH AS INFLUENZA AND PERTUSSIS. THIS WORK BECAME EVEN MORE IMPORTANT OVER THE PAST FEW YEARS AS OPPORTUNITIES TO STUDY COVID EMERGED. THE GOAL OF SIGNIFICANTLY REDUCING RSV IN THE NEONATE ALONG WITH THE MORBIDITY AND MORTALITY CONTINUES TO BE A SERIOUS PROBLEM. AS A RESULT, MORE COMPANIES HAVE ENTERED THE FIELD AND THE COMMITMENT TO THIS RESEARCH QUESTION HAS EXPANDED. WOMB HAS BEEN FORTUNATE TO PLAY A SMALL ROLL IN THIS RESEARCH. THIS WORK BRIDGES THE MATERNAL-NEONATAL FIELDS WHICH HISTORICALLY HAS BEEN DIFFICULT TO DO. LOOKING FORWARD THERE WILL BE ONGOING OPPORTUNITIES TO EXPAND ON THIS WORK AS ADDITIONAL RSV VACCINES ARE STUDIED. THERE IS ALSO THE POTENTIAL OPPORTUNITY TO STUDY GBS VACCINATION WHICH IF CONFIRMED TO PROVIDE ADEQUATE PROTECTION WOULD DRAMATICALLY CHANGE HOW WE CURRENTLY MANAGE THIS PERINATAL RISK. OTHER ACTIVE RESEARCH ACTIVITIES INCLUDE:1.PFIZER DEVELOPED AN RSV VACCINE AND BROUGHT IT TO THE CLINICAL MARKET IN AUGUST 2023. THE RCT THAT ENABLED THIS NOVEL PRODUCT WAS LAUNCHED IN 2018. A PHASE 2B RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PERFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY. THE ENROLLMENT FOR THIS STUDY SPANNED SEVERAL YEARS BECAUSE OF THE SEASONALITY OF RSV. PFIZER RECEIVED FDA APPROVAL FOR THIS NOVEL THERAPY BUT AS PART OF THAT APPROVAL WAS REQUIRED TO CONTINUE MATERNAL AND NEONATAL SURVIELLANCE FOR A PERIOD OF 24 MONTHS WHICH IS ONGING. WE CONTINUE TO PARTICIPATE IN THIS TRIAL SINCE THE MATERNAL AND FETAL OUTCOME EXTEND 24 MONTHS PAST DELIVERY.2. GSK ALSO INITIATED ITS OWN RSV VACCINE TRIAL IN 2021. THE PROPRIETRY FORMULATION IS DIFFERENT, BUT THE BASIC CONSTRUCT OF THE PHASE III, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL IS SIMILAR. THIS INTERNATIONAL TRIAL WAS DESIGNED TO ESTABLISH THE EFFICACY OF A SINGLE DOSE OF UNADJUVANTED RSV MATERNAL VACCINE, ADMINISTERED IM TO PREGNANT WOMEN 18 TO 49 YEARS OF AGE, FOR PREVENTION OF RSV ASSOCIATED LRTI IN THEIR INFANTS UP TO 6 MONTHS OF AGE. THE DSMB NOTICED A DISTURBING SAFETY SIGNAL AND CALLED FOR THE TRIAL TO BE HAULTED. SUBSEQUENTLY GSK SUSPENDED THE TRIAL BUT HAS COMMITTED TO LONGER TERMS SURVIELLANCE OF THE STUDY SUBJECTS.3. WHILE WOMB REMAINS CO |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt | 0 | 0 |
| IRS990EZ/ProgramSrvcAccomplishmentGrp/ProgramServiceExpensesAmt | 0 | 157058 |
| IRS990EZ/ProhibitedTaxShelterTransInd | 0 | 0 |
| IRS990EZ/RelatedOrganizationCtrlEntInd | 0 | 0 |
| IRS990EZ/SalariesOtherCompEmplBnftAmt | 0 | 97499 |
| IRS990EZ/ScheduleBNotRequiredInd | 0 | X |
| IRS990EZ/SchoolOperatingInd | 0 | 0 |
| IRS990EZ/StatesWhereCopyOfReturnIsFldCd | 0 | AZ |
| IRS990EZ/SubjectToProxyTaxInd | 0 | 0 |
| IRS990EZ/SumOfTotalLiabilitiesGrp/BOYAmt | 0 | 1865 |
| IRS990EZ/SumOfTotalLiabilitiesGrp/EOYAmt | 0 | 729 |
| IRS990EZ/TanningServicesProvidedInd | 0 | 0 |
| IRS990EZ/TaxImposedOnOrganizationMgrAmt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4911Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4912Amt | 0 | 0 |
| IRS990EZ/TaxImposedUnderIRC4955Amt | 0 | 0 |
| IRS990EZ/TaxReimbursedByOrganizationAmt | 0 | 0 |
| IRS990EZ/TotalExpensesAmt | 0 | 157058 |
| IRS990EZ/TotalProgramServiceExpensesAmt | 0 | 157058 |
| IRS990EZ/TotalRevenueAmt | 0 | 68014 |
| IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd | 0 | 0 |
| IRS990EZ/TypeOfOrganizationCorpInd | 0 | X |
| IRS990EZ/WebsiteAddressTxt | 0 | WWW.WOMB.ORG |
| IRS990ScheduleA/HospitalNameAndAddressGrp/CityNm | 0 | TUCSON |
| IRS990ScheduleA/HospitalNameAndAddressGrp/StateAbbreviationCd | 0 | AZ |
| IRS990ScheduleA/HospitalNameAndAddressGrp/SupportedOrganizationName/BusinessNameLine1Txt | 0 | TUCSON MEDICAL CENTER |
| IRS990ScheduleA/MedicalResearchOrganizationInd | 0 | X |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 0 | DESCRIPTION: INTEREST INCOME. AMOUNT: 17. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 1 | DESCRIPTION: INSURANCE. AMOUNT: 9,758. DESCRIPTION: TELEPHONE . AMOUNT: 2,121. DESCRIPTION: BANK CHARGES. AMOUNT: 111. DESCRIPTION: INTEREST EXPENSE. AMOUNT: 58. DESCRIPTION: OFFICE SUPPLIES. AMOUNT: 3,562. DESCRIPTION: CALIBRATION. AMOUNT: 1,340. DESCRIPTION: PENALTIES. AMOUNT: 896. TOTAL TO FORM 990-EZ, LINE 16: 17,846. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 2 | DESCRIPTION: PRIOR PERIOD ADJUSTMENTS. AMOUNT: 2,557. |
| IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt | 3 | DESCRIPTION: ACCOUNTS PAYABLE. BEG. OF YEAR AMOUNT: 1,865. END OF YEAR AMOUNT: 729. |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 0 | FORM 990-EZ, PART I, LINE 4 - OTHER INVESTMENT INCOME |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 1 | FORM 990-EZ, PART I, LINE 16 - OTHER EXPENSES |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 2 | FORM 990-EZ, PART I, LINE 20 - OTHER CHANGES IN NET ASSETS |
| IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc | 3 | FORM 990-EZ, PART II, LINE 26 - OTHER LIABILITIES |
| TransferPrsnlBnftContractsDecl/DeclarationDesc | 0 | THE ORGANIZATION DID NOT, DURING THE YEAR, RECEIVE ANY FUNDS, DIRECTLY,OR INDIRECTLY, TO PAY PREMIUMS ON A PERSONAL BENEFIT CONTRACT.THE ORGANIZATION, DID NOT, DURING THE YEAR, PAY ANY PREMIUMS, DIRECTLY,OR INDIRECTLY, ON A PERSONAL BENEFIT CONTRACT. |
| ReturnHeader/BuildTS | 0 | 2025-03-06 01:10:19Z |
| ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd | 0 | 1 |
| ReturnHeader/BusinessOfficerGrp/PersonNm | 0 | DR HUGH MILLER |
| ReturnHeader/BusinessOfficerGrp/PersonTitleTxt | 0 | CEO |
| ReturnHeader/BusinessOfficerGrp/PhoneNum | 0 | 5209071461 |
| ReturnHeader/BusinessOfficerGrp/SignatureDt | 0 | 2025-05-14 |
| ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt | 0 | WATCHING OVER MOTHERS & BABIES |
| ReturnHeader/Filer/BusinessNameControlTxt | 0 | WATC |
| ReturnHeader/Filer/EIN | 0 | 522420995 |
| ReturnHeader/Filer/PhoneNum | 0 | 5209071461 |
| ReturnHeader/Filer/USAddress/AddressLine1Txt | 0 | CO HUGH MILLER |
| ReturnHeader/Filer/USAddress/CityNm | 0 | TUCSON |
| ReturnHeader/Filer/USAddress/StateAbbreviationCd | 0 | AZ |
| ReturnHeader/Filer/USAddress/ZIPCd | 0 | 85712 |
| ReturnHeader/IRSResponsiblePrtyInfoCurrInd | 0 | 0 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmEIN | 0 | 860360084 |
| ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt | 0 | HBL CPAS PC |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt | 0 | 5470 E BROADWAY BLVD |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm | 0 | TUCSON |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd | 0 | AZ |
| ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd | 0 | 85711 |
| ReturnHeader/PreparerPersonGrp/PhoneNum | 0 | 5208863181 |
| ReturnHeader/PreparerPersonGrp/PreparerPersonNm | 0 | LAURA RANDOL |
| ReturnHeader/ReturnTs | 0 | 2025-05-14T17:46:49-05:00 |
| ReturnHeader/ReturnTypeCd | 0 | 990EZ |
| ReturnHeader/TaxPeriodBeginDt | 0 | 2023-07-01 |
| ReturnHeader/TaxPeriodEndDt | 0 | 2024-06-30 |
| ReturnHeader/TaxYr | 0 | 2023 |
Document Assets
No mirrored PDF or thumbnail assets are attached yet.